Skip to main content

Brainard Diana's Form 4 filing

Kalaris Therapeutics, Inc.KLRS · filed Nov 20, 2024

Accession no.
0000950170-24-129257
Filed
Nov 20, 2024
Trade date
Nov 19, 2024
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market sales total $4.79K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brainard DianaCIK 0001818070Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 19, 2024Common StockSSaleDisposed−8,706$0.55F2−$4,788.3723,363Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)